MNG1194
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.707
- G2M_CHECKPOINT+0.620
- MYC_TARGETS_V2+0.557
- MYC_TARGETS_V1+0.550
- MTORC1_SIGNALING+0.402
- UNFOLDED_PROTEIN_RESPONSE+0.401
- DNA_REPAIR+0.367
- MITOTIC_SPINDLE+0.349
- PROTEIN_SECRETION+0.308
- SPERMATOGENESIS+0.284
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.541
- ALLOGRAFT_REJECTION-0.532
- IL6_JAK_STAT3_SIGNALING-0.529
- INTERFERON_ALPHA_RESPONSE-0.524
- INTERFERON_GAMMA_RESPONSE-0.522
- INFLAMMATORY_RESPONSE-0.482
- COAGULATION-0.424
- COMPLEMENT-0.363
- APOPTOSIS-0.345
- KRAS_SIGNALING_UP-0.331
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1195 | — | — | 0.953 |
| 2 | MNG592 | — | — | 0.929 |
| 3 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.925 |
| 4 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.919 |
| 5 | MNG797 | — | — | 0.914 |
| 6 | BS_N6N147BY | Embryonal tumors | — | 0.914 |
| 7 | MNG1000 | — | — | 0.912 |
| 8 | TCGA-63-A5M9-01A-11R-A26W-07 | — | cohortSQ2 | 0.910 |
| 9 | BS_MVW01FPB | ATRT | — | 0.901 |
| 10 | MNG1178 | — | — | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.707 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.557 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.402 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.401 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.367 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.349 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.308 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.284 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.249 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.132 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.114 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.061 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.054 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.037 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.008 | Inavolisib | — uncovered |